ArticleOncotarget2010
A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.
Article in Oncotarget, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Rewired mNature communications · 2023Article
- Snail Promotes Cancer Cell Proliferation via Its Interaction with the BIRC3.Biomolecules & therapeutics · 2022Article
- DNA Repair and Immune Response Pathways Are Deregulated in Melanocyte-Keratinocyte Co-cultures Derived From the Healthy Skin of Familial Melanoma Patients.Frontiers in medicine · 2021Article
- Global gene expression of histologically normal primary skin cells from BCNS subjects reveals "single-hit" effects that are influenced by rapamycin.Oncotarget · 2019Article
- Prostaglandin EThe Journal of biological chemistry · 2019Article
- Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers.Communications biology · 2019Article
- Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation.Oncotarget · 2017Article
- Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells.The Journal of biological chemistry · 2016Article
- Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.International journal of experimental pathology · 2016Article
- p53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.Oncotarget · 2014Article
- p53 protein regulates Hsp90 ATPase activity and thereby Wnt signaling by modulating Aha1 expression.The Journal of biological chemistry · 2014Article
- Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter.The Journal of biological chemistry · 2013Article
- Heritable one-hit events defining cancer prevention?Cell cycle (Georgetown, Tex.) · 2013Article
- A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions.Oncotarget · 2013Article
- Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.Oncotarget · 2013Article
- Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.Cell cycle (Georgetown, Tex.) · 2012Article
- Rapalogs in cancer prevention: anti-aging or anticancer?Cancer biology & therapy · 2012Review
- dNTP Supply Gene Expression Patterns after P53 Loss.Cancers · 2012Article
- Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Specific changes in gene expression during cancer initiation should enable discovery of biomarkers for risk assessment, early detection and targets for chemoprevention. It has been previously demonstrated that altered mRNA and proteome signatures of morphologically normal cells bearing a single inherited "hit" in a tumor suppressor gene parallel many changes observed in the corresponding sporadic cancer. Here, we report on the global gene expression profile of morphologically normal, cultured primary breast epithelial and stromal cells from Li-Fraumeni syndrome (LFS) TP53 mutation carriers. Our analyses identified multiple changes in gene expression in both morphologically normal breast epithelial and stromal cells associated with TP53 haploinsufficiency, as well as interlocking pathways. Notably, a dysregulated p53 signaling pathway was readily detectable. Pharmacological intervention with the p53 rescue compounds CP-31398 and PRIMA-1 provided further evidence in support of the central role of p53 in affecting these changes in LFS cells and treatment for this cancer. Because loss of signaling mediated by TP53 is associated with the development and survival of many human tumors, identification of gene expression profiles in morphologically normal cells that carry "one-hit" p53 mutations may reveal novel biomarkers, enabling the discovery of potential targets for chemoprevention of sporadic tumors as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.